Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- OncoTherapy Science to Start Clinical Trial for Cancer Treatment Antibody in France
October 18, 2011
- Takeda Appoints Davidsen Head of Emerging Markets, Nycomed
October 18, 2011
- R-Tech Ueno to Resume Development of Treatment for Dry Eye
October 18, 2011
- NBI, Eli Lilly Japan to Establish “Special Position” for Trazenta in DPP-4 Inhibitor Market
October 18, 2011
- US MediciNova to Jointly Conduct Clinical Trials of MN-221 with Kissei
October 17, 2011
- Bayer, Onyx Restructure Global Oncology Partnership
October 17, 2011
- Ube, Santen Enter into License Agreement for EP2 Agonist
October 17, 2011
- MTPC Licenses Novel Pruritus Treatment from Toray in North America
October 17, 2011
- IBL Launches ANGPTL2 Assay Kit
October 17, 2011
- 60% Rule Likely to Replace 70% Rule for New Generics: Mr Kikuchi of Nichi-Iko MPI
October 17, 2011
- Otsuka Medical Devices to Acquire KiSCO Group Companies
October 17, 2011
- CMIC Forms a Chinese Joint Venture, Making Capital Investment in Local CRO
October 14, 2011
- Nichi-Iko to Be Delisted from OSE, NSE
October 14, 2011
- Nichi-Iko Revises Full-year Forecasts Downward Despite Double-digit Growth in Sales
October 14, 2011
- Daiichi Sankyo Resubmits NDA for Iron Deficiency Anemia Treatment Injectafer to FDA
October 14, 2011
- Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
- Nihon Chouzai Aims to Triple Home Healthcare, Nursing Facility Business in 2 Years
October 14, 2011
- Eli Lilly Japan Applies for Strattera for AD/HD in Adults
October 13, 2011
- Hisamitsu Posts 2.7% Loss in Mar-Aug Results on Shipping Adjustments of Main Products
October 13, 2011
- Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…